<span item_type="fundamental" item_id="e59f526cbee7d91d016ac388d82a8be9" counter_id="ST/US/VSTM" env="prod"></span><span item_type="announcement" item_id="579043371111613825" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 11.24 M, beating the estimate of USD 5.756 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -1.35.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -41.58 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Net product revenue for Q3 2025 was $11.2 million, compared to $0.0 million for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-2.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Total operating expenses for Q3 2025 were $52.0 million, compared to $37.0 million for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Cost of sales associated with product revenue was $1.7 million for Q3 2025, compared to $0.0 for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Research &amp; development expenses for Q3 2025 were $29.0 million, compared to $24.8 million for Q3 2024, an increase of $4.2 million or 16.9%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Selling, general &amp; administrative expenses for Q3 2025 were $21.0 million, compared to $12.3 million for Q3 2024, an increase of $8.7 million or 70.7%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Net loss (GAAP basis) for Q3 2025 was $98.5 million, or $1.35 per share (basic and diluted), compared to $24.0 million, or $0.60 per share (basic and diluted) for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Non-GAAP adjusted net loss for Q3 2025 was $39.4 million, or $0.54 per share (diluted), compared to non-GAAP adjusted net loss of $35.3 million, or $0.88 per share (diluted), for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>GAAP operating expenses for Q3 2025 were $52.0 million, while non-GAAP operating expenses were $49.8 million, excluding stock-based compensation expense of $2.18 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-2.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Verastem Oncology ended Q3 2025 with $137.7 million in cash and cash equivalents.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Cash, cash equivalents, and short-term investments totaled $137.7 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-2.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li>The company began commercial sales of the AVMAPKI FAKZYNJA CO-PACK within the United States following receipt of FDA approval in May 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>The company has a credit facility with Oberland Finance, allowing up to $150 million in a series of notes, with $75 million currently outstanding and an additional $75 million available upon achieving predefined milestones.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-2.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>With existing cash, product revenue, and exercise of cash warrants, the company has an expected cash runway into the second half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm"></span></li><li>Verastem, Inc. expects to continue strong execution of its product launch and plans to engage with the FDA to discuss development paths forward, including potential registration-directed trials in PDAC and NSCLC in the first half of 2026. The company also anticipates reporting updates on various clinical trials, including RAMP 205 and VS-7375, in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-2.htm"></span></li></ul>

Verastem | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 11.24 M